NCT05199948Active, not recruiting
Weight, Energy, Lipids, and the Liver (WELL) Study
Weight, Energy, Lipids, and the Liver (WELL) Study: Dietary Fat Quality and Ectopic Lipids in the Liver
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy metabolism in participants who consume 3 study foods per day for 16 week, while maintaining their body weight.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 74 (estimated)
- First submitted
- 5 Jan 2022
- Start date
- 2 May 2022
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- Ohio State University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT05199948
What you commit to
- Study type: Interventional
- Planned participants: 74
- From 2 May 2022 to the primary completion date, 1 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous diagnosis of severe kidney failure or diseases, some liver and pulmonary diseases
- Current or previous diagnosis of type 1 diabetes
- Use of Vitamin E supplements or Actos and Glucagon-like Peptide-1 medications for less than 1 months prior to enrolling.
- Use of medications where consuming the food products would be contraindicated
- Use of supplements high in linoleic acid in the past 4 weeks prior to enrolling
- Alcohol or drug abuse
- Metal implants or metallic foreign objects in the body
Other illness
- Unstable management of heart failure, heart disease events within 3 months, a need for heart surgeries or procedures, and/or the use of a pacemaker or defibrillator
- Severe or uncontrolled circulatory diseases and autoimmune diseases
- Current diagnosis of or current treatment of cancer other than non-melanoma skin cancer
- Gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) that would prevent participants from tolerating the study foods
- Food Allergy or intolerances
Other
- Any dietary restriction where consumption of the study foods, study meals/snack or meal challenge or any ingredient would be contraindicated
- Hyperthyroidism
- Pregnancy and lactation
- Inability to access veins for venipuncture
- Claustrophobia
Who the study is looking for
- Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) or similar
- Body Mass Index of 20-55 kg/m2
Age in the registry: 22 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Ohio State University Human Nutrition Laboratory Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
Related publications
- Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.Diabetes Obes Metab · 2026 · PMID 42677730
- Plasma linoleic acid is related to lower hepatic steatosis index and higher linoleate-rich cardiolipin in adults with MAFLD.Am J Physiol Gastrointest Liver Physiol · 2026 · PMID 41811730
This page is information, not medical advice. Discuss any trial with your doctor.